Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.
BACKGROUND
Type 2M von Willebrand disease (VWD) is characterized by a qualitative defect in von Willebrand factor (VWF) and diagnosed by a disproportionate decrease in VWF ristocetin cofactor activity (VWF:RCo) as compared with VWF antigen (VWF:Ag).


OBJECTIVE
We report here on the spurious diagnosis of VWD in a patient with a sequence variation in the ristocetin-binding domain of VWF.


METHODS
The index case had a VWF:RCo of 11 IU dL(-1), with VWF:RCo/VWF:Ag ratio of 0.09. DNA sequencing revealed a novel P1467S mutation in a known ristocetin-binding region of the A1 domain. Because of the discrepancy between the laboratory findings, consistent with type 2M VWD, and the patient's lack of bleeding symptoms, further studies were performed to determine whether this mutation affected VWF function or merely reduced its ability to interact with ristocetin.


RESULTS
Studies with recombinant VWF showed normal platelet binding with botrocetin, but a significant decrease in binding in response to ristocetin. Ristocetin-induced binding to recombinant GPIb was also absent, but normal binding was seen when a gain-of-function GPIb construct was used in the absence of ristocetin. VWF function under shear stress was normal when analyzed with a cone and plate(let) analyzer.


CONCLUSIONS
The decreased VWF:RCo seen with the P1467S sequence variation likely represents an artifact as a result of the use of ristocetin to measure VWF activity. The normal VWF function in other assays correlates with the lack of hemorrhagic symptoms, and suggests the need for more physiologically relevant assays of VWF function.
Flood
V H
VH
Division of Hematology/Oncology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA. vflood@mcw.edu
Friedman
K D
KD
Gill
J C
JC
Morateck
P A
PA
Wren
J S
JS
Scott
J P
JP
Montgomery
R R
RR
D001665:Binding Sites / Q000235:genetics; D002648:Child; D005260:Female; D006801:Humans; D020125:Mutation, Missense; D010979:Platelet Function Tests; D011485:Protein Binding / Q000235:genetics; D012310:Ristocetin; D014842:von Willebrand Diseases / Q000175:diagnosis*; D014841:von Willebrand Factor / Q000235:genetics / Q000502:physiology*
D014841:von Willebrand Factor; D012310:Ristocetin
Otolaryngol Head Neck Surg. 1997 Dec;117(6):628-32
9419090
Thromb Haemost. 2000 Jan;83(1):107-13
10669163
J Thromb Haemost. 2006 Oct;4(10):2103-14
16889557
J Clin Invest. 1973 Nov;52(11):2708-16
4542944
J Thromb Haemost. 2004 Jun;2(6):892-8
15140124
Blood. 1995 Aug 1;86(3):1010-8
7620154
Thromb Haemost. 1993 Feb 1;69(2):192-6
8456433
Thromb Haemost. 1990 Oct 22;64(2):326-32
1702906
Blood. 1996 Oct 1;88(7):2559-68
8839848
Biochemistry. 1989 Oct 17;28(21):8317-26
2557900
Blood. 1982 Jul;60(1):201-7
6805535
Blood. 2000 Jan 1;95(1):164-72
10607699
J Thromb Haemost. 2003 Oct;1(10):2191-7
14521604
Thromb Res. 1986 Aug 1;43(3):303-11
3090735
J Biol Chem. 1988 Dec 5;263(34):17901-4
2461363
Biochemistry. 1992 Nov 17;31(45):11144-51
1359905
Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9846-9
1409710
J Thromb Haemost. 2007 Dec;5(12):2547-9
17944987
Annu Rev Biochem. 1998;67:395-424
9759493
Br J Haematol. 1981 Nov;49(3):455-64
6975118
Semin Thromb Hemost. 2007 Nov;33(8):727-44
18175279
Thromb Diath Haemorrh. 1971 Oct 31;26(2):362-9
5316292
Haemophilia. 2008 Mar;14(2):171-232
18315614
J Thromb Haemost. 2007 Sep;5(9):1914-22
17596142
Structure. 2002 Jul;10(7):943-50
12121649
J Biol Chem. 1991 May 5;266(13):8149-55
2022635
J Thromb Haemost. 2005 Dec;3(12):2607-11
16150051
Thromb Haemost. 2000 Sep;84(3):401-9
11019962
N Engl J Med. 1958 Jul 24;259(4):156-61
13566439
Blood. 1998 Mar 1;91(5):1572-81
9473222
Haematologica. 2004 Jan;89(1):77-85
14754609
J Thromb Haemost. 2006 Apr;4(4):766-73
16634745
Thromb Res. 2000 Aug 15;99(4):353-61
10963786
J Clin Invest. 1973 Nov;52(11):2697-707
4201262
Thromb Res. 1997 Feb 15;85(4):283-94
9062952
Blood. 1973 May;41(5):687-90
4540393
Thromb Haemost. 2000 Jan;83(1):127-35
10669166